tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

ANRO Stock Latest News

Company AnnouncementsAlto Neuroscience Strengthens Financial Position Amid Increased R&D
7d ago
ANRO
Alto Neuroscience price target lowered to $10 from $32 at Stifel
PremiumThe Fly
Alto Neuroscience price target lowered to $10 from $32 at Stifel
8d ago
ANRO
Alto Neuroscience reports Q3 EPS (62c), consensus (65c)
PremiumThe Fly
Alto Neuroscience reports Q3 EPS (62c), consensus (65c)
8d ago
ANRO
Alto Neuroscience expects cash balance to support operations into 2027
PremiumThe Fly
Alto Neuroscience expects cash balance to support operations into 2027
8d ago
ANRO
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
10d ago
CXW
GEO
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
17d ago
CGC
EDR
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
22d ago
EDR
EMB
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
27d ago
CGC
LAC
Alto Neuroscience falls -67.3%
PremiumThe Fly
Alto Neuroscience falls -67.3%
29d ago
ANRO
Alto Neuroscience falls -61.5%
PremiumThe Fly
Alto Neuroscience falls -61.5%
29d ago
ANRO
Alto Neuroscience falls -62.8%
PremiumThe Fly
Alto Neuroscience falls -62.8%
29d ago
ANRO
Morning Movers: AT&T rises and Coca-Cola falls following quarterly reports
PremiumThe Fly
Morning Movers: AT&T rises and Coca-Cola falls following quarterly reports
29d ago
T
BA
Wedbush downgrades Alto Neuroscience to Neutral following ALTO-100 readout
PremiumThe FlyWedbush downgrades Alto Neuroscience to Neutral following ALTO-100 readout
29d ago
ANRO
Alto Neuroscience downgraded to Neutral from Outperform at Wedbush
Premium
The Fly
Alto Neuroscience downgraded to Neutral from Outperform at Wedbush
29d ago
ANRO
Alto Neuroscience downgraded to Neutral from Buy at Rodman & Renshaw
Premium
The Fly
Alto Neuroscience downgraded to Neutral from Buy at Rodman & Renshaw
29d ago
ANRO
Alto Neuroscience price target lowered to $10 from $32 at Baird
PremiumThe Fly
Alto Neuroscience price target lowered to $10 from $32 at Baird
29d ago
ANRO
Alto Neuroscience CEO says ‘strong cash balance to support us’
PremiumThe Fly
Alto Neuroscience CEO says ‘strong cash balance to support us’
30d ago
ANRO
Alto Neuroscience falls 47% after announcing ALTO-100 did not meet endpoint
PremiumThe Fly
Alto Neuroscience falls 47% after announcing ALTO-100 did not meet endpoint
30d ago
ANRO
Alto Neuroscience’s Phase 2b study of ALTO-100 did not meet primary endpoint
PremiumThe Fly
Alto Neuroscience’s Phase 2b study of ALTO-100 did not meet primary endpoint
30d ago
ANRO
Alto Neuroscience falls -3.8%
PremiumThe FlyAlto Neuroscience falls -3.8%
1M ago
ANRO
Four new option listings and one option delisting on September 18th
Premium
The Fly
Four new option listings and one option delisting on September 18th
2M ago
ANRO
EGIO
Alto Neuroscience: No demonstrative efficacy in MDD patients with vortioxetine
Premium
The Fly
Alto Neuroscience: No demonstrative efficacy in MDD patients with vortioxetine
3M ago
ANRO

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >